Genotropin (somatropin)

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Short Stature Born Small for Gestational Age (SGA)

Conditions

Short Stature Born Small for Gestational Age (SGA)

Trial Timeline

Oct 1, 2002 → Aug 1, 2015

About Genotropin (somatropin)

Genotropin (somatropin) is a approved stage product being developed by Pfizer for Short Stature Born Small for Gestational Age (SGA). The current trial status is completed. This product is registered under clinical trial identifier NCT01859949. Target conditions include Short Stature Born Small for Gestational Age (SGA).

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01859949ApprovedCompleted

Competing Products

20 competing products in Short Stature Born Small for Gestational Age (SGA)

See all competitors
ProductCompanyStageHype Score
somatropin + leuprorelinEli LillyPhase 3
77
Growth HormoneEli LillyApproved
85
Pancreatic EnzymeAbbViePhase 2
52
Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth HormoneAstraZenecaPhase 3
77
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)MerckPhase 1
33
Saizen® + Saizen®MerckPhase 3
77
r-metHuLeptinAmgenPhase 1
32
Somapacitan + Norditropin®Novo NordiskPhase 2
51
Somatotropin growth hormone recombinant humanPfizerApproved
84
Genotropin + GenotropinPfizerPhase 3
76
GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatmentPfizerApproved
84
GenotropinPfizerPhase 2/3
64
glepaglutideZealand PharmaPhase 3
74
GlepaglutideZealand PharmaPhase 3
74
ZP1848Zealand PharmaPhase 2
49
glepaglutide + PlaceboZealand PharmaPhase 3
74
GlepaglutideZealand PharmaPhase 3
74
Glepaglutide 10 mgZealand PharmaPhase 3
74
GlepaglutideZealand PharmaPhase 3
74
Nutropin [Somatropin (rDNA origin) for injection]IpsenApproved
82